Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Syneos Health Inc    SYNH

SYNEOS HEALTH INC

(SYNH)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Syneos Health Schedules Fourth Quarter and Year End 2018 Earnings Call for Monday, March 18, 2019

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/14/2019 | 05:46pm EDT

MORRISVILLE, N.C., March 14, 2019 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization combining a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), will release its fourth quarter and year end 2018 financial results and file its Form 10-K for the fiscal year ended December 31, 2018, after the market closes on Monday, March 18, 2019. The Company will host its earnings call at 5:30 p.m. ET that afternoon.

Participants may access the conference call live via webcast on the Investor Relations section of the Syneos Health website at investor.syneoshealth.com. To participate via telephone, please dial +1 877 930 8058 within the United States or +1 253 336 7551 outside the United States, approximately 15 minutes prior to the scheduled start time. The conference ID for the call is 3768756.

A webcast replay will be available on the Investor Relations section of the Syneos Health website at investor.syneoshealth.com after 8:30 p.m. on March 18. In addition, an audio replay will be available for one week following the call and will be accessible by dialing +1 855 859 2056 within the United States or +1 404 537 3406 outside the United States. The replay ID is 3768756.

About Syneos Health
Syneos Health™ (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together more than 23,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life® visit syneoshealth.com.

   
Investor Relations Contact: Press/Media Contact:
Ronnie Speight Danielle DeForge
Senior Vice President, Investor Relations Executive Director, External Communications
+1 919 745 2745 +1 781 425 2624
investor.relations@syneoshealth.com danielle.deforge@syneoshealth.com
   

Syneos Health_rgb_tm.png


© GlobeNewswire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SYNEOS HEALTH INC
05:01pSYNEOS HEALTH : to Present at Upcoming Investor Conferences
AQ
05/13MEDIDATA NEXT LONDON 2019 : Blending the Best of Clinical Development, AI-Enable..
AQ
05/09Syneos Health Leaders Honored by the Healthcare Businesswomen's Association f..
GL
05/09SYNEOS HEALTH : 1Q Earnings Snapshot
AQ
05/09SYNEOS HEALTH : Reports First Quarter 2019 Results
AQ
05/09SYNEOS HEALTH, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
05/09SYNEOS HEALTH : Management's Discussion and Analysis of Financial Condition and ..
AQ
04/29SYNEOS DEADLINE TOMORROW : Rosen Law Firm Reminds Syneos Health, Inc. Investors ..
BU
04/255-DAY DEADLINE ALERT : Kessler Topaz Meltzer & Check, LLP Announces Deadline in ..
BU
04/22Syneos Health Wins Best CRO Award at the Vaccine Industry Excellence Awards
GL
More news
Financials ($)
Sales 2019 4 676 M
EBIT 2019 560 M
Net income 2019 103 M
Debt 2019 2 483 M
Yield 2019 -
P/E ratio 2019 58,26
P/E ratio 2020 24,20
EV / Sales 2019 1,45x
EV / Sales 2020 1,29x
Capitalization 4 307 M
Chart SYNEOS HEALTH INC
Duration : Period :
Syneos Health Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SYNEOS HEALTH INC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 54,7 $
Spread / Average Target 32%
EPS Revisions
Managers
NameTitle
Alistair John Macdonald Chief Executive Officer & Director
John M. Dineen Chairman
Jason Michael Meggs Chief Financial Officer & Executive Vice President
Kenneth F. Meyers Independent Director
Linda S. Harty Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SYNEOS HEALTH INC5.49%4 307
IQVIA HOLDINGS INC15.06%26 365
LONZA GROUP21.91%22 880
CELLTRION, INC.--.--%20 217
INCYTE CORPORATION20.82%16 475
EXACT SCIENCES CORPORATION52.20%12 402